FDA approves Lilly pill for common advanced breast cancer

U.S. regulators have approved a new medicine for treating a common type of breast cancer that has spread to other parts of the body.

Posted: Sep. 30, 2017 2:07 AM
Updated: Sep. 30, 2017 2:07 AM
Scroll for more content...

By LINDA A. JOHNSON
AP Medical Writer

U.S. regulators have approved a new medicine for treating a common type of breast cancer that has spread to other parts of the body.

Eli Lilly's Verzenio (verr-ZEHN'ee-oh) was approved Thursday by the Food and Drug Administration for patients with what's called HR-positive, HER2-negative breast cancer that has worsened after hormone therapy.

According to the FDA, about 72 percent of patients with breast cancer have this type.

The daily pill is to be used either alone, after hormone therapy and chemotherapy have stopped working, or in combination with a hormone therapy called fulvestrant.

Indianapolis-based Eli Lilly says Verzenio, which is taken until cancer resumes growing, will cost $10,948 per month. It's offering patients financial assistance, including 12 months with a minimal copayment for those with commercial insurance.

Copyright 2017 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Related Content

Article Comments

Terre Haute
Overcast
76° wxIcon
Hi: 78° Lo: 63°
Feels Like: 76°
Robinson
Overcast
74° wxIcon
Hi: 76° Lo: 63°
Feels Like: 74°
Zionsville
Overcast
71° wxIcon
Hi: 74° Lo: 61°
Feels Like: 71°
Rockville
Overcast
76° wxIcon
Hi: 75° Lo: 62°
Feels Like: 76°
Casey
Broken Clouds
75° wxIcon
Hi: 75° Lo: 63°
Feels Like: 75°
Brazil
Overcast
76° wxIcon
Hi: 75° Lo: 63°
Feels Like: 76°
Marshall
Overcast
76° wxIcon
Hi: 78° Lo: 62°
Feels Like: 76°
Isolated storms, but cooler.
WTHI Planner
WTHI Temps
WTHI Radar

WTHI Events